Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MKC

McCormick & Co., Inc

Feb 13 • 04:00PM ET

71.49

-0.16 -0.22 %

Consumer Defensive • Packaged Foods • USA • NYSE

Peers: CHD HRL SYY K GIS KHC CPB MDLZ CAG PEP

| Held by: VTI VOO VO IVV SPY XLP SDY RSP NOBL VTV

Index	S&P 500	P/E	24.37	EPS (ttm)	2.93	Insider Own	6.27%	Shs Outstand	253.50M	Perf Week	6.04%
Market Cap	19.19B	Forward P/E	21.31	EPS next Y	3.35	Insider Trans	-1.53%	Shs Float	251.62M	Perf Month	4.26%
Enterprise Value	23.35B	PEG	3.11	EPS next Q	0.62	Inst Own	83.73%	Short Float	4.64%	Perf Quarter	8.52%
Income	789.40M	P/S	2.81	EPS this Y	3.27%	Inst Trans	0.34%	Short Ratio	3.36	Perf Half Y	1.85%
Sales	6.84B	P/B	3.34	EPS next Y	8.26%	ROA	6.01%	Short Interest	11.68M	Perf YTD	4.96%
Book/sh	21.37	P/C	200.11	EPS next 5Y	6.85%	ROE	14.32%	52W High	86.24 -17.10%	Perf Year	-7.77%
Cash/sh	0.36	P/FCF	25.92	EPS past 3/5Y	5.10% 1.08%	ROIC	8.76%	52W Low	59.62 19.91%	Perf 3Y	-5.42%
Dividend Est.	1.92 (2.68%)	EV/EBITDA	17.64	Sales past 3/5Y	2.51% 4.08%	Gross Margin	37.90%	Volatility	2.61% 3.06%	Perf 5Y	-20.26%
Dividend TTM	1.83 (2.56%)	EV/Sales	3.41	EPS Y/Y TTM	0.10%	Oper. Margin	15.97%	ATR (14)	1.86	Perf 10Y	59.45%
Dividend Ex-Date	Dec 29, 2025	Quick Ratio	0.28	Sales Y/Y TTM	1.73%	Profit Margin	11.54%	RSI (14)	67.32	Recom	2.24
Dividend Gr. 3/5Y	6.74% 7.74%	Current Ratio	0.70	EPS Q/Q	5.45%	SMA20	9.26%	Beta	0.57	Target Price	73.64
Payout	61.43%	Debt/Eq	0.74	Sales Q/Q	2.91%	SMA50	7.72%	Rel Volume	1.17	Prev Close	71.65
Employees	14100	LT Debt/Eq	0.57	Earnings	Jan 22 BMO	SMA200	3.35%	Avg Volume	3.48M	Price	71.49
IPO	Mar 17, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.85% 0.31%	Trades		Volume	4,073,808	Change	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-25	Upgrade	Deutsche Bank	Hold → Buy	$75
Aug-20-25	Upgrade	JP Morgan	Neutral → Overweight	$83
Jun-16-25	Initiated	UBS	Neutral	$83
Mar-27-25	Downgrade	Argus	Buy → Hold
Jan-08-25	Upgrade	TD Cowen	Hold → Buy	$86 → $90
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$85 → $91
Jun-12-24	Upgrade	Citigroup	Sell → Neutral	$68 → $69
Apr-02-24	Upgrade	Argus	Hold → Buy
Feb-01-24	Initiated	Citigroup	Sell	$60
Jan-22-24	Downgrade	Consumer Edge Research	Overweight → Equal Weight
Sep-22-23	Initiated	HSBC Securities	Hold	$86
Sep-13-23	Initiated	TD Cowen	Market Perform	$87
Jun-06-23	Upgrade	BofA Securities	Underperform → Buy	$75 → $100
Apr-14-23	Resumed	Stifel	Hold	$82
Mar-10-23	Initiated	UBS	Sell	$71
Jan-27-23	Upgrade	Bernstein	Mkt Perform → Outperform	$90
Nov-15-22	Initiated	Exane BNP Paribas	Outperform	$94
Jul-06-22	Downgrade	Argus	Buy → Hold
Feb-17-22	Upgrade	Argus	Hold → Buy	$112
Jan-19-22	Downgrade	Credit Suisse	Outperform → Neutral	$100

Show Previous Ratings

Feb-15-26 10:00PM	The Break Is Over. Companies Are Jacking Up Prices Again. (The Wall Street Journal)
Feb-13-26 07:00PM	3 Highest-yielding Dividend Aristocrats That'll Pay You For Generations (Barchart)
Feb-12-26 08:34AM	Is Wall Street Bullish or Bearish on McCormick & Company Stock? (Barchart)
Feb-10-26 01:44PM	Analyst Report: McCormick & Company, Incorporated (Morningstar Research)
08:43AM	UBS Reduces PT on McCormick & Company (MKC) Stock (Insider Monkey)
11:02PM	Loading…
Feb-08-26 11:02PM	McCormick (MKC): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Feb-03-26 09:05AM	Barclays Reviews McCormick (MKC) as ERP and Tax Pressures Come Into Focus (Insider Monkey)
Jan-30-26 04:32AM	McCormick tackles $50M tariff hit through pricing, other measures (Supply Chain Dive)
Jan-29-26 03:44PM	The Earnings Impact of Tariffs (Zacks)
12:34AM	The Top 5 Analyst Questions From McCormick's Q4 Earnings Call (StockStory)
Jan-27-26 05:53PM	BofA Stays Positive on McCormick (MKC) Despite Weaker Q4 Results (Insider Monkey)
Jan-26-26 04:30PM	McCormick & Company to Present at Consumer Analyst Group of New York Conference (PR Newswire)
Jan-25-26 08:00AM	Are consumer staples stocks still worth investing in? (Yahoo Finance Video)
Jan-23-26 02:15PM	Your Favorite Spices May Get a Bit More Expensive Soon. Here's the Reason Why (Investopedia)
01:09PM	CEOs Flag Jittery US Consumers as Global Tensions Intensify (Bloomberg)
09:07AM	Loading…
09:07AM	McCormick Q4 Earnings Lag Estimates, Organic Sales Grow (Zacks)
08:58AM	Company News for Jan 23, 2026 (Zacks)
12:32AM	MKC Q4 Deep Dive: Margin Pressures Offset Modest Sales Growth as Guidance Clouds Outlook (StockStory)
Jan-22-26 04:36PM	Stocks Settle Higher as Global Tensions Cool and the Economy Expands (Barchart) -8.05%
03:50PM	Meta's bullish call, Alibaba's AI chip unit, McCormick earnings (Yahoo Finance Video)
03:31PM	Analyst Report: McCormick & Company, Incorporated (Morningstar Research)
03:06PM	Russell 2000 Extends Records, Meta Jumps 5%: What's Moving Markets Thursday? (Benzinga)
02:10PM	McCormick Raises Prices as Higher Costs Hurt Profitability (The Wall Street Journal)
02:01PM	McCormick & Co Inc (MKC) Q4 2025 Earnings Call Highlights: Navigating Growth Amid Inflation ... (GuruFocus.com)
01:47PM	Procter & Gamble Q2 Earnings Beat Estimates, Organic Sales Flat Y/Y (Zacks)
01:08PM	McCormick & Company, Incorporated Q4 Earnings Call Highlights (MarketBeat)
12:56PM	Why McCormick (MKC) Stock Is Nosediving (StockStory)
12:30PM	Medifast's Q4 Guidance Remains Weak: When Does Growth Return? (Zacks)
11:40AM	KRYAY or MKC: Which Is the Better Value Stock Right Now? (Zacks)
10:58AM	Spice Giant McCormick Stumbles, CEO Blames Inflation, Tariffs (Benzinga)
10:19AM	Loading…
10:19AM	Spice Maker McCormick Plans to Raise Prices Further to Offset Tariffs (The Wall Street Journal)
09:41AM	Stocks to Watch Thursday: Intel, P&G, GE Aerospace (The Wall Street Journal)
09:30AM	Compared to Estimates, McCormick (MKC) Q4 Earnings: A Look at Key Metrics (Zacks)
08:59AM	Service Corporation's Strategic Focus: What's Driving Stability Now? (Zacks)
08:20AM	McCormick Logs Higher Sales, Gives Soft Full-Year 2026 Outlook (The Wall Street Journal)
07:40AM	McCormick (MKC) Lags Q4 Earnings and Revenue Estimates (Zacks)
07:26AM	This Spice Maker's Stock Is Tumbling After Earnings. What We Know. (Barrons.com)
07:26AM	McCormick Logs Higher Quarterly Sales, Projects Continued Annual Growth (The Wall Street Journal)
06:48AM	McCormick: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
06:46AM	McCormick's (NYSE:MKC) Q4 CY2025 Sales Top Estimates But Stock Drops (StockStory)
06:30AM	McCORMICK REPORTS STRONG 2025 FINANCIAL RESULTS AND PROVIDES 2026 OUTLOOK (PR Newswire)
Jan-21-26 07:00PM	Trump EU meeting, Intel earnings, December PCE: What to Watch (Yahoo Finance Video)
04:15PM	McCormick Appoints Gavin Hattersley and Rick Dierker to Board of Directors (PR Newswire)
01:21PM	Brown-Forman Advances on Strong Brands and Premiumization (Zacks)
10:34AM	Can B&G Foods' Margin Improvement Hold Amid Soft Demand? (Zacks)
08:57AM	Hormel Foods International Sales: Still a Growth Engine? (Zacks)
Jan-20-26 10:07PM	McCormick (MKC) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
12:27PM	Can Boston Beer's Margin Surge Compensate for Soft Volume Trends? (Zacks)
11:28AM	McCormick Q4 Earnings Coming Up: What Investors Need to Understand (Zacks)
11:02AM	Jim Cramer on McCormick: "I Frankly Don't Know If It's Capable of Really Beating the Numbers Anymore" (Insider Monkey)
Jan-18-26 07:30AM	Trump in Davos, Netflix and Intel results on deck earnings season ramps: What to watch this week (Yahoo Finance)
07:30AM	Trump in Davos, Netflix and Intel results on deck as earnings season ramps: What to watch this week (Yahoo Finance)
07:30AM	Trump in Davos, Netflix and Intel results on deck as earnings season ramps up: What to watch this week (Yahoo Finance)
Jan-16-26 07:00PM	Trump at Davos, Netflix earnings, SCOTUS hearing: What to Watch (Yahoo Finance Video)
12:30PM	Why Clorox Stock Remains Worth Holding in Your Portfolio Now? (Zacks)
09:15AM	Seeking Clues to McCormick (MKC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
09:09AM	Beyond Meat Builds on Protein Strengths With Launch of Beyond Immerse (Zacks)
08:14AM	How Is B&G Foods Reshaping Its Brand Portfolio for Growth? (Zacks)
Jan-15-26 12:20PM	Is Constellation Brands Poised to Gain Share Amid Category Headwinds? (Zacks)
10:04AM	AB InBev Bolsters Position With Premiumization and Digital Expansion (Zacks)
10:00AM	McCormick (MKC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:47AM	Can Brand Diversification Shield PPC From Commodity Volatility? (Zacks)
Jan-14-26 10:52AM	Can McCormick's Innovation & Distribution Wins Offset Cost Pressures? (Zacks)
Jan-13-26 12:01PM	Is Colgate's Cost Discipline Enough in a Softer Demand Cycle? (Zacks)
09:53AM	Can Tyson Foods' Chicken Segment Drive Consistent Profit Growth? (Zacks)
09:01AM	Are Sysco's U.S. Foodservice Operations Gaining Executional Traction? (Zacks)
Jan-12-26 08:55AM	J.M. Smucker's Pet Food Sales Soft: Is Demand Normalizing Yet? (Zacks)
Jan-09-26 12:30PM	SMPL Stock Jumps 7% After Posting Earnings & Sales Beat in Q1 (Zacks)
08:04AM	HELE Q3 Earnings Meet Estimates, Home & Outdoor Sales Decline Y/Y (Zacks)
07:57AM	Service Corporation Revenue Mix: What's Powering the Top Line? (Zacks)
07:39AM	Lamb Weston Streamlines Global Footprint to Improve Efficiency (Zacks)
Jan-08-26 12:52PM	Medifast Shifts to Metabolic Health: A Durable Growth Path? (Zacks)
10:27AM	Constellation Brands Posts Q3 Earnings Beat, Soft Wine & Spirits Sales (Zacks)
09:38AM	Church & Dwight Accelerates Innovation to Defend Market Share (Zacks)
09:12AM	United Natural Foods' Natural vs. Conventional: Margin Divide Widens? (Zacks)
09:00AM	Flowers Foods Faces Margin Pressure: Can Profitability Recover? (Zacks)
06:22AM	McCormick to Invest $750 Million for Majority Control of Mexican Joint Venture (GuruFocus.com)
Jan-06-26 11:07AM	McCormick Takes Majority Control in Mexico JV: Growth Lever in 2026? (Zacks)
Jan-02-26 04:00PM	McCormick Completes Acquisition of Controlling Interest in McCormick de Mexico (PR Newswire)
Dec-31-25 11:33PM	3 S&P 500 Stocks We Keep Off Our Radar (StockStory)
Dec-29-25 08:41PM	Analyst Report: McCormick & Company, Incorporated (Morningstar Research)
Dec-23-25 06:34AM	McCormick & Company's Quarterly Earnings Preview: What You Need to Know (Barchart)
Dec-22-25 09:00AM	McCormick & Company to Report 2025 Fourth Quarter Financial Results on January 22, 2026 (PR Newswire)
Dec-21-25 05:30AM	Makers of Everyday Essentials Once Offered Investors Safety. Do They Still? (The Wall Street Journal)
Dec-15-25 10:35PM	Reflecting On Shelf-Stable Food Stocks' Q3 Earnings: McCormick (NYSE:MKC) (StockStory)
10:20AM	McCormick's Q3 Volumes Gain Traction: What to Expect in 2026? (Zacks)
09:16AM	Here Are Mondays Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More (24/7 Wall St.)
Dec-11-25 03:10AM	How Is McCormicks Stock Performance Compared to Other Food & Beverage Stocks? (Barchart)
Dec-02-25 11:03PM	3 Reasons to Avoid MKC and 1 Stock to Buy Instead (StockStory)
12:40PM	MKC's Q3 Shows Solid Consumer Momentum: Will the Strength Last in 2026? (Zacks)
Dec-01-25 03:49PM	3 Fresh Dividend Hikes That Might Be Telling You Something (MarketBeat)
Nov-26-25 10:14AM	Flavor Solutions Lifts MKC's Q3 Results: Will the Growth Last? (Zacks)
Nov-19-25 08:00AM	McCormick Raises Quarterly Dividend: A Look at Its Growth Strategy (Zacks)
Nov-18-25 11:38PM	1 Cash-Producing Stock Worth Investigating and 2 We Turn Down (StockStory)
06:14PM	What's on the Thanksgiving Table? A Stock Pick for Every Course (MarketBeat)
04:50PM	McCormick Announces Increase in Quarterly Dividend (PR Newswire)
10:57AM	Will McCormick Be Able to Sustain Its 2% Organic Growth in 2026? (Zacks)
Nov-17-25 09:29AM	JPMorgan sees major EPS tailwinds for these food producers from new tariff relief (Investing.com)
Nov-13-25 04:15PM	Are Wall Street Analysts Bullish on McCormick & Company Stock? (Barchart)
Nov-12-25 07:00AM	Sick of hearing about the AI trade? BofA offers 16 hot stock picks that go far beyond tech. (MarketWatch)

McCormick & Co., Inc. engages in the manufacturing, marketing, and distribution of spices, seasoning mixes, condiments, and other flavorful products to retail outlets, food manufacturers, and foodservice businesses. The firm offers the Aeroplane, Billy Bee, Cattlemen's BBQ Sauce, Cholula, Club House, Club House for Chefs, Drogheria & Alimentari, Ducros, El Guapo, FONA, Frank's RedHot, French's, and other related brands. It operates through the Consumer and Flavor Solutions segments. The Consumer segment sells spices, seasonings, condiments, and sauces. The Flavor Solutions segment includes seasoning blends, spices and herbs, condiments, coating systems, and compound flavors. The company was founded by Willoughby M. McCormick in 1889 and is headquartered in Baltimore, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kurzius Lawrence Erik	10% Owner	Feb 12 '26	Option Exercise	49.02	50,000	2,451,250	346,992	Feb 13 12:05 PM
Kurzius Lawrence Erik	10% Owner	Feb 12 '26	Sale	71.63	50,000	3,581,500	296,992	Feb 13 12:05 PM
MANGAN MICHAEL D	Director	Feb 09 '26	Option Exercise	49.96	5,000	249,800	48,029	Feb 10 02:10 PM
MANGAN MICHAEL D	Director	Feb 09 '26	Sale	67.92	5,000	339,600	43,029	Feb 10 02:10 PM
MANGAN MICHAEL D	Director	Feb 05 '26	Option Exercise	49.96	5,000	249,800	46,780	Feb 09 03:50 PM
Tapiero Jacques	Director	Feb 05 '26	Option Exercise	49.96	5,000	249,800	36,596	Feb 09 03:41 PM
Tapiero Jacques	Director	Feb 05 '26	Sale	67.09	5,000	335,450	31,596	Feb 09 03:41 PM
Schwartz Jeffery D	Vice President, Gen Counsel	Feb 03 '26	Option Exercise	49.96	10,000	499,600	100,028	Feb 05 01:20 PM
Tapiero Jacques	Director	Feb 03 '26	Option Exercise	49.96	5,000	249,800	36,596	Feb 04 02:22 PM
Tapiero Jacques	Director	Feb 03 '26	Sale	63.85	5,000	319,250	31,596	Feb 04 02:22 PM
Tapiero Jacques	Director	Feb 02 '26	Option Exercise	61.10	6	348	31,596	Feb 03 12:30 PM
Kurzius Lawrence Erik	10% Owner	Jan 13 '26	Option Exercise	49.96	50,000	2,498,000	296,762	Jan 14 04:03 PM
Kurzius Lawrence Erik	10% Owner	Jan 13 '26	Sale	67.43	50,000	3,371,500	246,762	Jan 14 04:03 PM
Tapiero Jacques	Director	Jan 02 '26	Option Exercise	67.28	792	53,310	31,590	Jan 06 03:53 PM
Brendan Foley	Affiliate	Nov 13 '25	Proposed Sale	65.56	57,144	3,746,361		Nov 13 05:44 PM
Foley Brendan M	Chairman, President & CEO	Nov 12 '25	Option Exercise	49.96	57,144	2,854,914	165,796	Nov 13 04:43 PM
Foley Brendan M	Chairman, President & CEO	Nov 12 '25	Sale	65.56	57,144	3,746,361	108,652	Nov 13 04:43 PM
Kurzius Lawrence Erik	10% Owner	Nov 11 '25	Sale	64.54	39,014	2,517,964	0	Nov 12 12:13 PM
Kurzius Lawrence Erik	10% Owner	Oct 08 '25	Option Exercise	49.96	50,000	2,498,000	296,762	Oct 10 09:40 AM
Kurzius Lawrence Erik	10% Owner	Oct 08 '25	Sale	65.86	50,000	3,293,000	246,762	Oct 10 09:40 AM
Schwartz Jeffery D	Vice President, Gen Counsel	Jul 01 '25	Option Exercise	49.96	10,000	499,600	83,957	Jul 02 10:25 AM
Jenkins Katherine	Chief Growth Officer	May 12 '25	Option Exercise	49.62	5,430	269,413	3,430	May 13 03:17 PM
Jenkins Katherine	Chief Growth Officer	May 12 '25	Sale	76.38	7,642	583,696	0	May 13 03:17 PM
Repas Gregory	V.P. & Controller	Apr 03 '25	Sale	81.42	2,750	223,905	2,266	Apr 04 12:13 PM
Kurzius Lawrence Erik	Director	Apr 02 '25	Option Exercise	49.96	50,000	2,498,000	297,437	Apr 02 02:43 PM
Kurzius Lawrence Erik	Director	Apr 02 '25	Sale	81.81	50,000	4,090,300	247,437	Apr 02 02:43 PM
Montiel Maritza Gomez	Director	Apr 01 '25	Option Exercise	52.98	5,912	313,188	12,850	Apr 02 02:41 PM
Montiel Maritza Gomez	Director	Apr 01 '25	Sale	82.67	5,912	488,745	6,938	Apr 02 02:41 PM
Schwartz Jeffery D	Vice President, Gen Counsel	Mar 31 '25	Option Exercise	49.96	20,000	999,200	89,958	Apr 01 01:19 PM
Jenkins Katherine	Chief Growth Officer	Mar 15 '25	Option Exercise	0.00	584	0	2,309	Mar 18 06:32 PM
Gabriel Marcos Mendes	Executive VP & CFO	Mar 15 '25	Option Exercise	0.00	1,069	0	9,641	Mar 18 06:32 PM
Sanchez Ana	President EMEA	Mar 15 '25	Option Exercise	0.00	648	0	5,441	Mar 18 06:25 PM
Tapiero Jacques	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	30,446	Mar 18 06:23 PM
Repas Gregory	V.P. & Controller	Mar 15 '25	Option Exercise	0.00	711	0	5,105	Mar 18 06:20 PM
Kurzius Lawrence Erik	Director	Mar 15 '25	Option Exercise	0.00	1,734	0	248,079	Mar 18 06:18 PM
Piper Sarah	Chief Human Relations Officer	Mar 15 '25	Option Exercise	0.00	212	0	3,331	Mar 18 06:14 PM
Foust Andrew	President, Americas	Mar 15 '25	Option Exercise	0.00	931	0	8,858	Mar 18 06:12 PM
THOMAS TERRY S	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	1,734	Mar 18 06:10 PM
Montiel Maritza Gomez	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	6,938	Mar 18 06:08 PM
PRESTON MARGARET M V	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	81,293	Mar 18 06:07 PM
Conway Michael Aaron	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	16,630	Mar 18 06:04 PM
BRAMMAN ANNE L	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	6,639	Mar 18 06:01 PM
MANGAN MICHAEL D	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	41,780	Mar 18 05:59 PM
LITTLE PATRICIA A	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	26,076	Mar 18 05:58 PM
VERNON W ANTHONY	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	11,826	Mar 18 05:56 PM
RODKIN GARY M	Director	Mar 15 '25	Option Exercise	0.00	1,344	0	12,110	Mar 18 05:54 PM

Open in Screener

NVCR

NovoCure Ltd

Feb 13 • 04:00PM ET

10.99

-1.54 -12.29 %

Healthcare • Medical Devices • United Kingdom • NASD

Peers: MDT BSX EW ISRG ZBH SYK TFX ALGN PEN RMD

| Held by: VTI VB IWM VBK VXF IWO IBB VTWO SCHA IHI

Index	RUT	P/E	-	EPS (ttm)	-1.61	Insider Own	10.00%	Shs Outstand	111.98M	Perf Week	8.38%
Market Cap	1.23B	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.73%	Shs Float	100.78M	Perf Month	-20.19%
Enterprise Value	992.58M	PEG	-	EPS next Q	-0.41	Inst Own	85.69%	Short Float	7.91%	Perf Quarter	-3.26%
Income	-177.65M	P/S	1.92	EPS this Y	10.17%	Inst Trans	2.03%	Short Ratio	4.45	Perf Half Y	-5.18%
Sales	642.27M	P/B	3.61	EPS next Y	-13.94%	ROA	-13.75%	Short Interest	7.97M	Perf YTD	-15.00%
Book/sh	3.05	P/C	1.19	EPS next 5Y	7.48%	ROE	-50.60%	52W High	22.95 -52.11%	Perf Year	-49.38%
Cash/sh	9.25	P/FCF	-	EPS past 3/5Y	-40.48% -83.87%	ROIC	-30.70%	52W Low	9.82 11.91%	Perf 3Y	-87.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.19% 11.49%	Gross Margin	75.52%	Volatility	11.32% 6.67%	Perf 5Y	-94.21%
Dividend TTM	-	EV/Sales	1.55	EPS Y/Y TTM	-15.64%	Oper. Margin	-27.37%	ATR (14)	1.00	Perf 10Y	-9.25%
Dividend Ex-Date	-	Quick Ratio	1.50	Sales Y/Y TTM	11.17%	Profit Margin	-27.66%	RSI (14)	42.24	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	-17.92%	SMA20	-9.12%	Beta	0.72	Target Price	25.21
Payout	-	Debt/Eq	2.34	Sales Q/Q	7.81%	SMA50	-14.06%	Rel Volume	1.99	Prev Close	12.53
Employees	1488	LT Debt/Eq	0.70	Earnings	Feb 26 BMO	SMA200	-21.52%	Avg Volume	1.79M	Price	10.99
IPO	Oct 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.37% 5.20%	Trades		Volume	3,568,545	Change	-12.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$14.50
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$30
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98

Show Previous Ratings

Feb-13-26 07:42AM	Novocures stock rises 37% on FDA clearance of pancreatic cancer treatment device (Medical Device Network) -12.29%
06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
Feb-12-26 05:43PM	Novocure Is Up 19%. FDA Approval Is Giving the Biotech Stock a Lift. (Barrons.com) +19.33%
04:35PM	These Stocks Are Todays Movers: AppLovin, Fastly, Micron, Cisco, QuantumScape, Novocure, AST SpaceMobile, and More (Barrons.com)
04:15PM	Stocks to Watch Thursday Recap: Cisco, McDonalds, AppLovin (The Wall Street Journal)
03:11PM	Loading…
03:11PM	Stock Market Today: S&P 500 Breaks Key Support As Techs Pace Sell-Off; Cancer Stock Vaults (Live Coverage) (Investor's Business Daily)
11:26AM	NovoCure Stock Surges After FDA Approves Optune Pax (Benzinga)
10:07AM	Stocks to Watch Thursday: Cisco, McDonald's, AppLovin (The Wall Street Journal)
06:53AM	This Biotech Stock Is Jumping 25% After Getting an FDA Boost (Barrons.com)
06:28AM	AppLovin shares slide after earnings, and other early market movers (MarketWatch)
06:19AM	Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report-Micron, Novocure, Fastly In Focus (Benzinga)
04:50AM	Stock Market Today: Dow, S&P 500 and Nasdaq point higher as tech finds its footing; Treasurys steady; precious metals dip. (MarketWatch)
Feb-11-26 09:55PM	NovoCure (NVCR) Stock Is Trending Overnight - Here's What You Should Know (Benzinga)
06:33PM	Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar (The Wall Street Journal)
05:54PM	U.S. FDA Approves Novocure's Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer (Business Wire)
08:10AM	Loading…
Feb-05-26 08:10AM	Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates (Zacks) -12.72%
Jan-12-26 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update (Business Wire)
Jan-07-26 03:58AM	Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? (Zacks)
Dec-22-25 07:00AM	Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-09-25 05:31AM	Medtronic changes investor relations leadership ahead of diabetes spinout (MedTech Dive) +5.31%
Dec-01-25 07:00AM	Novocure Appoints Company President Frank Leonard as Chief Executive Officer (Business Wire) -8.82%
Nov-26-25 07:00AM	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-12-25 10:00AM	2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon (Motley Fool)
07:00AM	Novocure to Participate in 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-30-25 04:22PM	NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
10:30AM	Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:17AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-15-25 07:00AM	Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress (Business Wire) +7.67%
07:00AM	Loading…
Oct-01-25 07:00AM	Novocure to Report Third Quarter 2025 Financial Results (Business Wire) +8.20%
Sep-29-25 04:30PM	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting (Business Wire)
Sep-16-25 05:28AM	Novocure obtains approval for Optune Lua device in Japan to treat NSCLC (Medical Device Network)
Sep-15-25 07:00AM	Novocure's Optune Lua Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
Aug-29-25 04:26AM	2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts (Motley Fool)
Aug-28-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
Aug-25-25 07:00AM	Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain (Business Wire) -5.87%
Aug-22-25 01:37PM	NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer (Zacks)
Aug-20-25 07:00AM	Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer (Business Wire)
Aug-13-25 12:08PM	Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) (Insider Monkey)
Jul-25-25 07:02AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 01:30PM	NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -24.05%
08:05AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Novocure Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-01-25 07:00AM	Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 (Business Wire)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
07:00AM	Novocure to Report Second Quarter 2025 Financial Results (Business Wire)
Jun-18-25 12:00PM	What Makes NovoCure (NVCR) a New Buy Stock (Zacks)
Jun-06-25 12:26PM	NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial (Zacks)
Jun-02-25 02:05PM	NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial (Benzinga) -10.83%
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
08:00AM	Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-28-25 06:57AM	1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
May-27-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
May-16-25 10:00AM	The Next Frontier to Treat Cancer: Electricity (The Wall Street Journal)
May-15-25 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? (Zacks)
Apr-29-25 09:55AM	Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? (Zacks)
Apr-25-25 01:21PM	Why NovoCure Stock Skyrocketed This Week (Motley Fool)
Apr-24-25 07:03PM	Why NovoCure Stock Leaped 4% Higher Today (Motley Fool)
10:34AM	NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 10:16AM	Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire) +7.63%
06:45AM	Novocures device for metastatic NSCLC treatment gains CE Mark (Medical Device Network)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks) +5.97%
07:09AM	Novocure's Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Apr-17-25 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-16-25 03:43PM	Why NovoCure Stock Was Withering on Wednesday (Motley Fool)
Apr-10-25 08:40AM	Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? (Zacks) -5.13%
Apr-01-25 07:00AM	Novocure to Report First Quarter 2025 Financial Results (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha)
Mar-04-25 07:00AM	Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference (Business Wire)
Feb-28-25 02:09AM	NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com)
Feb-27-25 03:30PM	NovoCure (NVCR) Q4 2024 Earnings Call Transcript (Motley Fool) -12.43%
10:00AM	NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (Business Wire)
Feb-20-25 10:00AM	NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jan-30-25 03:14PM	Jim Cramer on NovoCure Limited (NVCR): I Have Watched Them For Years And Years And Theyre Not Making Money (Insider Monkey)
Jan-22-25 04:00AM	Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland (Business Wire)
Jan-13-25 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update (Business Wire)
Jan-03-25 07:00AM	Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-14-24 06:50AM	Novocure price target raised to $42 from $28 at Piper Sandler (TipRanks)
Dec-06-24 08:32AM	Why NovoCure Stock Was Winning Big This Week (Motley Fool) +5.11%
Dec-05-24 04:29AM	Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? (Motley Fool) -9.00%
Dec-03-24 02:51PM	Novocure Stock Earns 96 RS Rating (Investor's Business Daily)
07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
Dec-02-24 04:23PM	Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds (Investor's Business Daily) +48.95%
01:20PM	Novocure seeks approval after pancreatic cancer wearable scores at Phase III (Clinical Trials Arena)
10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
09:54AM	Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success (GuruFocus.com)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
07:00AM	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
06:08AM	Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date (BioPharma Dive)
Nov-27-24 07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire) +10.12%
Nov-21-24 11:58AM	Novocure secures FDA approval for add-ons to brain cancer treatment wearable (Medical Device Network)
07:05AM	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma (Business Wire)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cordova Ashley	Chief Executive Officer	Sep 05 '25	Buy	12.22	81,550	996,859	437,569	Sep 08 07:10 AM
Brackmann Christoph	Chief Financial Officer	Jul 29 '25	Buy	11.59	20,000	231,800	141,150	Jul 30 04:33 PM
Stafford Kristin	Director	Jun 03 '25	Sale	17.28	999	17,259	3,054	Jun 04 04:26 PM
LEUNG GABRIEL	Director	Jun 03 '25	Sale	17.31	999	17,297	81,229	Jun 04 04:24 PM
Madden Martin J.	Director	Jun 03 '25	Sale	17.19	999	17,176	18,674	Jun 04 04:23 PM
Scannell Timothy J	Director	Jun 03 '25	Sale	17.32	999	17,299	6,018	Jun 04 04:22 PM
HILLEMAN JERYL L	Director	Jun 03 '25	Sale	17.26	999	17,247	5,591	Jun 04 04:17 PM
Ocean Allyson J	Director	Jun 03 '25	Sale	17.29	999	17,269	3,054	Jun 04 04:16 PM
VERNON W ANTHONY	Director	Jun 03 '25	Sale	17.35	999	17,329	167,887	Jun 04 04:14 PM
Hung David	Director	Jun 03 '25	Sale	17.30	999	17,280	12,195	Jun 04 04:11 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Jun 02 '25	Sale	17.50	30,196	528,413	168,452	Jun 04 04:09 PM
FRANCIS LEONARD	Officer	Jun 02 '25	Proposed Sale	19.11	30,196	577,046		Jun 02 04:25 PM
Paravasthu Mukund	Chief Operating Officer	May 03 '25	Sale	17.91	592	10,604	83,556	May 05 04:17 PM
MUKUND PARAVASTHU	Officer	May 05 '25	Proposed Sale	17.91	592	10,604		May 05 04:05 PM
Weinberg Uri	Chief Innovation Officer	Mar 03 '25	Sale	18.92	268	5,071	166,243	Mar 04 04:19 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 03 '25	Sale	18.54	2,527	46,841	143,673	Mar 04 04:19 PM
Cordova Ashley	Chief Executive Officer	Mar 03 '25	Sale	18.54	2,053	38,055	204,005	Mar 04 04:19 PM
Paravasthu Mukund	Chief Operating Officer	Mar 03 '25	Sale	18.54	250	4,634	29,173	Mar 04 04:16 PM
FRANCIS LEONARD	Officer	Mar 03 '25	Proposed Sale	18.54	2,527	46,841		Mar 03 05:34 PM
MUKUND PARAVASTHU	Officer	Mar 03 '25	Proposed Sale	18.54	250	4,634		Mar 03 05:31 PM
URI WEINBERG	Officer	Mar 03 '25	Proposed Sale	18.92	268	5,071		Mar 03 05:20 PM
ASHLEY CORDOVA	Officer	Mar 03 '25	Proposed Sale	18.54	2,053	38,055		Mar 03 05:18 PM
WILHELMUS GROENHUYSEN	Officer	Mar 03 '25	Proposed Sale	18.54	3,165	58,667		Mar 03 05:13 PM
Weinberg Uri	Chief Innovation Officer	Feb 28 '25	Sale	18.75	4,637	86,949	166,511	Mar 03 04:28 PM
Leupin Nicolas	Chief Medical Officer	Feb 27 '25	Sale	20.02	991	19,844	50,133	Mar 03 04:28 PM
Puri Michal Nath	Chief Human Resources Officer	Feb 27 '25	Sale	20.02	1,387	27,773	108,706	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 27 '25	Sale	20.02	12,266	245,609	148,970	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '25	Sale	18.28	2,770	50,648	146,200	Mar 03 04:27 PM
Cordova Ashley	Chief Executive Officer	Feb 27 '25	Sale	20.02	11,153	223,323	208,399	Mar 03 04:26 PM
Cordova Ashley	Chief Executive Officer	Feb 28 '25	Sale	18.28	2,341	42,804	206,058	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 27 '25	Sale	20.02	1,646	32,959	29,791	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 28 '25	Sale	18.28	368	6,729	29,423	Mar 03 04:26 PM
URI WEINBERG	Officer	Feb 28 '25	Proposed Sale	18.75	4,637	86,949		Feb 28 05:01 PM
MUKUND PARAVASTHU	Officer	Feb 28 '25	Proposed Sale	18.28	368	6,729		Feb 28 04:50 PM
ASHLEY CORDOVA	Officer	Feb 28 '25	Proposed Sale	18.28	2,341	42,803		Feb 28 04:43 PM
WILHELMUS GROENHUYSEN	Officer	Feb 28 '25	Proposed Sale	18.28	3,202	58,546		Feb 28 04:40 PM
FRANCIS LEONARD	Officer	Feb 28 '25	Proposed Sale	18.28	2,770	50,647		Feb 28 04:38 PM
MUKUND PARAVASTHU	Officer	Feb 27 '25	Proposed Sale	20.02	1,646	32,959		Feb 27 04:42 PM
ASHLEY CORODVA	Officer	Feb 27 '25	Proposed Sale	20.02	11,153	223,322		Feb 27 04:39 PM
WILHELMUS GROENHUYSEN	Officer	Feb 27 '25	Proposed Sale	20.02	7,211	144,389		Feb 27 04:36 PM
FRANCIS LEONARD	Officer	Feb 27 '25	Proposed Sale	20.02	12,266	245,608		Feb 27 04:28 PM

MKC

McCormick & Co., Inc

NVCR

NovoCure Ltd

Upgrade your FINVIZ experience